METHOD FOR DETERMINING RISK OF METABOLICALLY ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH TRUNCAL OBESITY Russian patent published in 2025 - IPC A61B5/103 G03B42/02 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to X-ray diagnostics, and can be used to determine the risk of metabolically associated fatty liver disease in patients with truncal obesity. Patient undergoes dual-energy X-ray absorptiometry in the “Whole body” mode of the ratio of the percentage content of fat in the truncal region to the percentage content of fat in the gynoid region (P0 value). Further, total body fat content (P1), subcutaneous adipose tissue area (P2) in square centimetres, visceral adipose tissue area (P3) in square centimetres, and percentage of abdominal body fat (P4) are determined. If P0 exceeds 1, the area of abdominal fat in the body (P5) is determined in square centimetres by summation of P2 and P3. Further, total fat area is calculated in square centimetres (P6) by formula P1*P5/P4. Further, the portion of visceral adipose tissue (P7) of total body fat is determined by formula P3/P6. If P7 exceeds 0.11, a risk of metabolically associated fatty liver disease is stated. If the P7 value does not exceed or is equal to 0.1, there is no risk of metabolically associated fatty liver disease.

EFFECT: method enables the non-invasive determination of the risk of metabolically associated fatty liver disease in the patients with truncal obesity by the values determined by the dual-energy X-ray absorptiometry in the “Whole body” mode.

1 cl, 2 ex